|9 Months Ended|
Sep. 30, 2016
|Restructuring And Related Activities [Abstract]|
7. Restructuring Charges
On July 22, 2015, the Company announced that the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet’s disease uveitis, run by Servier, did not meet the primary endpoint of increased time to first acute ocular exacerbation. Due to the results and the Company’s belief they would be predictive of results in its other EYEGUARD studies, in August 2015 XOMA announced its intention to end the EYEGUARD global Phase 3 program. On August 21, 2015, the Company, in connection with its efforts to lower operating expenses and preserve capital while continuing to focus on its endocrine product pipeline, implemented a restructuring plan (the “2015 Restructuring”) that included a workforce reduction resulting in the termination of 52 employees during the second half of 2015.
During the nine months ended September 30, 2016, the Company recorded a charge of $15,000, related to severance costs and contract termination costs resulting from the 2015 Restructuring. There were no such charges during the three months ended September 30, 2016. During the three and nine months ended September 30, 2015, the Company recorded a charge of $2.2 million related to severance costs and a charge of $0.4 million related to contract termination costs resulting from the 2015 Restructuring.
The outstanding restructuring liabilities are included in accrued and other liabilities on the condensed consolidated balance sheets. The components of the restructuring liabilities are shown below (in thousands):
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
Reference 1: http://www.xbrl.org/2003/role/presentationRef